Antibody binding specifically to CD40 and use thereof

CD96-BINDING AGENTS AS IMMUNOMODULATORS

WNT SIGNALING AGONIST MOLECULES

METHODS OF ADMINISTERING ANTI-OX40 ANTIBODIES

TREM2 STABILIZING ANTIBODIES

BISPECIFIC ANTIBODIES AGAINST CD9

STROMAL GENE SIGNATURES FOR DIAGNOSIS AND USE IN IMMUNOTHERAPY

Compositions and Methods for Vaccination and the Treatment of Infectious Diseases

ANTI-CD3-BINDING DOMAINS AND ANTIBODIES COMPRISING THEM, AND METHODS FOR THEIR GENERATION AND USE

SHEDDING BLOCKING AGENTS WITH INCREASED STABILITY

IMMUNOTHERAPY WITH COMBINATION THERAPY COMPRISING AN IMMUNOTOXIN

Method of treating an ocular condition by administering a humanized monoclonal antibodies that target VE-PTP (HPTP-Beta)

METHODS FOR TREATING DYSREGULATED LIPID METABOLISM

Anti-TREM1 antibodies and methods of use thereof

METHODS OF ADMINISTERING ANTI-OX40 ANTIBODIES

POLYPEPTIDE VARIANTS AND USES THEREOF

NOTCH3 Agonist Compositions and Methods for Treating Small Vessel Diseases

ANTI-TIM-3 ANTIBODIES AND COMPOSITIONS

NOVEL COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES

BISPECIFIC ANTIBODIES AGAINST CD9 AND CD7

METHODS FOR THE TREATMENT OF CANCER

TREATMENT OF DISEASES RELATED TO ATP-BINDING CASSETTE TRANSPORTER 1 DYSFUNCTION USING TREM2 AGONISTS

HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1)

ANTIBODY CONSTRUCTS BINDING 4-1BB AND TUMOR-ASSOCIATED ANTIGENS AND USES THEREOF

IL12 RECEPTOR AGONISTS AND METHODS OF USE THEREOF

ANTI-BCMA/ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF

ANTI-TNFR2 ANTIBODY AND USES THEREOF

EXPRESSION OF SEQUENCE-ENGINEERED LAMBDA ANTIBODY LIGHT CHAINS

BINDING MOLECULES AGAINST CD3 AND USES THEREOF

IMMUNOMODULATING TUMOR NECROSIS FACTOR RECEPTOR 25 (TNFR25) AGONISTS, ANTAGONISTS, AND IMMUNOTOXINS

INTERFERON-ASSOCIATED ANTIGEN BINDING PROTEINS FOR USE IN TREATING HEPATITIS B INFECTION

METHODS AND PRODUCTS FOR REDUCING SIDE EFFECTS ASSOCIATED WITH USE OF IMMUNE AGONIST ANTIBODIES

MULTISPECIFIC ANTIBODY

ANTIBODY VARIANT COMBINATIONS AND USES THEREOF

ANTI-DEATH RECEPTOR ANTIBODIES AND METHODS OF USE THEREOF

Methods for inhibiting tumor growth or treating cancer by administering an immunoglobulin single variable domain that binds glucocorticoid-induced TNFR family-related receptor (GITR)

Anti-TrkB monoclonal antibodies and methods of use

POSITIVE ALLOSTERIC MODULATORS OF THE CALCIUM-SENSING RECEPTOR

NOVEL ANTI-CD3 ANTIBODIES

BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO PD1 AND LAG3

MODULATION OF IMMUNE RESPONSE USING BTLA AGONIST ANTIBODIES

METHODS FOR SELECTIVE EXPANSION OF GAMMA DELTA T-CELL POPULATIONS AND COMPOSITIONS THEREOF

ANTI-TNFR2 ANTIBODIES AND METHODS OF USE

FUSION POLYPEPTIDES BINDING ANTIBODY FC DOMAINS AND INTEGRIN AND METHODS OF USE

PHARMACEUTICAL COMBINATIONS COMPRISING A FURAZANOBENZIMIDAZOLES AND A CD40 AGONIST FOR USE IN THE TREATMENT OF NEOPLASTIC DISEASES

CD123 binding proteins and related compositions and methods

Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signaling

METHODS AND COMPOSITIONS FOR OX40 ACTIVATION IN TREATMENT OF CANINE CANCER

BISPECIFIC PROTEIN

METHODS OF TREATING CANCER

Anti-CD40 antibodies and uses thereof

Markers of acute myeloid leukemia stem cells

PD-L1 BINDING PROTEINS COMPRISING SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CD8+ T CELL ANTIGENS

METHODS OF TREATING CANCER USING TNFRSF25 ANTIBODIES

Anti-SIRPa antibodies and methods of use thereof

Anti-SIRPa antibodies and their therapeutic applications

ANTI-TNFR2 ANTIBODIES AND USES THEREOF

METHODS OF TREATMENT USING A LEPTIN RECEPTOR AGONIST ANTIBODY

ANTIBODY TO LEPTIN RECEPTOR

MONOSPECIFIC ANTI-FRIZZLED ANTIBODIES AND METHODS OF USE

Markers of acute myeloid leukemia stem cells

BINDING MOLECULE SPECIFIC FOR LRIG-1 PROTEIN AND USE THEREOF

BISPECIFIC ANTIBODY TARGETING OF T REGULATORY CELLS FOR TREATMENT OF INFLAMMATORY CONDITIONS

MULTI-SPECIFIC ANTIGEN-BINDING MOLECULE HAVING ALTERNATIVE FUNCTION TO FUNCTION OF BLOOD COAGULATION FACTOR VIII

METHODS AND COMPOSITIONS FOR INDUCING NOTCH SIGNALING IN TUMOR MICROENVIRONMENTS

TUMOR IMMUNOTHERAPY USING SINDBIS VIRAL VECTORS AND AGONIST MONOCLONAL ANTIBODIES

BISPECIFIC ANTIBODY BINDING TO CD40 AND FAP

ANTIBODIES BINDING TO GPRC5D

IL2Rbeta/common gamma chain antibodies

Bispecific Antibodies for Activation of Immune Cells

4-1BB AND OX40 BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS, ANTIBODIES AGAINST 4-1BB, ANTIBODIES AGAINST OX40

Anti-4-1BB antibody and use thereof

C3D CELLULAR AND ACELLULAR VACCINES FOR THE PREVENTION AND TREATMENT OF CANCER

ANTI-CD137 ANTIBODIES AND METHODS OF USE THEREOF

ACTIVATING ANTI-GAL9 BINDING MOLECULES

ANTIBODIES THAT BIND HUMAN CD27 AND USES THEREOF

Anti-TEM1 antibodies and antigen-binding portions thereof

NOVEL MODULATORS

ANTI-C-MET AGONIST ANTIBODY AND USE THEREOF

Anti-c-Met agonist antibody and use thereof

ANTI-LAG-3 BINDING MOLECULES

ANTIBODY SUBSTITUTING FOR FUNCTION OF BLOOD COAGULATION FACTOR VIII

Bispecific polypeptides against CD137

Immunomodulatory antibodies

COMPOSITIONS AND METHODS FOR AUGMENTING ANTIBODY MEDIATED RECEPTOR SIGNALING

ANTI-CD137 MOLECULES AND USE THEREOF

ANTIBODIES AGAINST HUMAN CD38

Anti-NPR1 antibodies and uses thereof

ANTIGEN-BINDING MOLECULE CONTAINING TWO ANTIGEN-BINDING DOMAINS THAT ARE LINKED TO EACH OTHER

Bispecific antibodies binding ALK-1 and BMPR-2

ANTI-AXL ANTIBODIES

Antibodies specific for hyperphosphorylated tau and methods of use thereof

Anti-MET antibodies and uses thereof

ANTIVIRAL IMMUNOTHERAPY BY MEMBRANE RECEPTOR LIGATION

Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR)

Anti-IGFBP-3R antibodies and methods of treating an IGFBP-3R expressing cancer

ANTI-VISTA ANTIBODIES AND FRAGMENTS

Antibodies to programmed cell death protein 1

TRAILshort antibody and methods of use

Trispecific and/or trivalent binding proteins

Bispecific anti-VEGF and anti-TrkB binding molecules for the treatment of eye diseases

Anti-TREM2 antibodies and methods of use thereof

MODULATORS OF CELL SURFACE PROTEIN INTERACTIONS AND METHODS AND COMPOSITIONS RELATED TO SAME

Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for use in medicine

ANTI-OX40 ANTIBODIES AND THEIR USES

Agonistic anti-tumor necrosis factor receptor 2 antibodies

Antigen-binding proteins that activate the leptin receptor

Immunoswitch nanoparticles for reprogrammed T cell responses

ANTI-CD137 ANTIBODIES AND METHODS OF USE THEREOF

ANTIBODIES COMPRISING MODIFIED HEAVY CONSTANT REGIONS

MULTIMERIC CD40 BINDING MOLECULES AND USES THEREOF

Multivalent and multispecific OX40-binding fusion proteins

Method of treating asthma with anti-IL1RAP antibodies

Protein binding domains stabilizing functional conformational states of GPCRS and uses thereof

ANTI-OX40 ANTIBODIES AND METHODS OF USE THEREOF

GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) ANTIBODIES AND METHODS OF USE THEREOF

NOVEL ICOS ANTIBODIES AND TUMOR-TARGETED ANTIGEN BINDING MOLECULES COMPRISING THEM

Immunoglobulins binding human Vγ9Vδ2 T cell receptors

FCMR-binding molecules and uses thereof

BISPECIFIC ANTIBODIES WITH TETRAVALENCY FOR A COSTIMULATORY TNF RECEPTOR

BTN3A binding proteins and uses thereof

FIXAXFX BISPECIFIC ANTIBODY WITH COMMON LIGHT CHAIN

Multivalent and multispecific DR5-binding fusion proteins and methods of modulating immune cells

CD137 agonist antibodies and uses thereof

METHODS AND COMPOSITIONS RELATING TO GLP1R VARIANTS

MODIFIED ANTIBODIES

ICOS BINDING PROTEINS

ANTI-TIGIT ANTIBODIES AND METHODS OF USE

Anti-PD-L1/anti-4-1BB bispecific antibodies and uses thereof

ANTIBODY MOLECULES THAT BIND PD-L1 AND CD137

Antibody molecules that bind CD137 and OX40

IGFR-like 2 receptor and uses thereof

BISPECIFIC ANTIGEN BINDING MOLECULES COMPRISING LIPOCALIN MUTEINS

ANTIBODY THERAPEUTICS THAT BIND CD137

BIFUNCTIONAL MOLECULE DIRECTED AGAINST HUMAN PD-1

Markers of acute myeloid leukemia stem cells

METHODS FOR TREATING DYSREGULATED LIPID METABOLISM

Agonistic CD28 antigen binding molecules targeting Her2

TIGIT and CD112R blockade

MUSK INHIBITION

Agonistic anti TNFR2 antibody molecules

COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES

Targeted Immunotolerance

WNT SIGNALING AGONIST MOLECULES

Method of treatment with a fusion protein comprising apelin and an anti-APLNR antibody

Variant antibodies that bind OX40

Antibodies targeting CD137 and methods of use thereof

Procoagulant antibodies

ANTIGEN-BINDING MOLECULES CAPABLE OF BINDING CD3 AND CD137 BUT NOT SIMULTANEOUSLY

ANTIBODY SUBSTITUTING FOR FUNCTION OF BLOOD COAGULATION FACTOR VIII

Bispecific antibody which binds to CD40 and EpCAM

HUMAN ANTIBODIES TO PD-L1

Anti-PD-1 antibodies

ANTI-TCR ANTIBODY MOLECULES AND USES THEREOF

MULTIVALENT RECEPTOR-CLUSTERING AGONIST ANTIBODY CONSTRUCTS

ANTIBODY SPECIFICALLY BINDING TO C-MET, AND USE THEREOF

Methods and compositions for treating cancer by targeting the CLEC2D-KLRB1 pathway

CD226 agonist antibodies

BIFUNCTIONAL BINDING POLYPEPTIDES

METHODS AND SYSTEMS FOR CONTROLLING THE AGONISTIC PROPERTIES OF ANTIBODY VARIABLE DOMAINS BY LIGHT

Anti-IL-5 Antibodies

Methods of Treating Cancer

Retroviral and lentiviral vectors

INDUCED STEM MEMORY T CELLS AND METHODS OF USE THEREOF

Mesothelin-targeted CD40 agonistic multispecific antibody constructs for the treatment of solid tumors

Engineered antibody Fc variants for enhanced serum half life

Gene Signatures for Determining ICOS Expression

MUSCARINIC ACETYLCHOLINE RECEPTOR BINDING AGENTS AND USES THEREOF

Antigen-binding polypeptides directed against CD38

Tie2-binding agents and methods of use

Anti-CD137 antigen-binding molecule and utilization thereof

Anti-DR5 antibodies and methods of use thereof

IMMUNOMODULATORY ANTIBODIES

METHODS OF USING ANTI-TREM2 ANTIBODIES

Mesothelin and CD137 binding molecules

Anti-CD40 antibody having engineered Fc domains and therapeutic uses thereof

Methods and compositions for treating autoimmune and inflammatory conditions

MULTI-SPECIFIC WNT SURROGATE MOLECULES AND USES THEREOF

Bispecific antibodies targeting immune checkpoints

KLOTHO BETA

Anti-TREM-2 agonist antibodies

BETA GLUCAN AND CD40 AGONIST COMBINATION IMMUNOTHERAPY

BTLA antibodies

Anti-SIRP-Beta1 antibodies and methods of use thereof

Antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3 and their uses

Trispecific T cell engagers

ANTI-GITR ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF

Anti-TrkB agonist antibodies binding to D1 domain of TrkB

Methods for the treatment of tissue lesions with CCR2 agonists

COMBINATION OF A TYPE II PROTEIN ARGININE METHYLTRANSFERASE INHIBITOR AND AN ICOS BINDING PROTEIN TO TREAT CANCER

COMPOSITIONS AND METHODS FOR ANTIBODY DELIVERY

COMBINED THERAPY WITH ICOS BINDING PROTEINS AND ARGININEMETHYLTRANSFERASE INHIBITORS

Nucleic acid molecules encoding binding agents to CD40 and 4-1BB (CD137)

NOVEL BISPECIFIC AGONISTIC 4-1BB ANTIGEN BINDING MOLECULES

Nucleic acids encoding antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)

ANTI-TIGIT ANTIBODIES AND METHODS OF USE

Methods of treating metastasis, including inhibiting bone cancer metastasis, by administering an antibody which binds connexin 43 (Cx43) hemichannel

REAGENTS AND METHODS FOR IDENTIFYING, ENRICHING, AND/OR EXPANDING ANTIGEN-SPECIFIC T CELLS

Bispecific T cell engagers

TRIMERIC POLYPEPTIDE COMPLEXES AND USES THEREOF

ANTI-CD137 ANTIBODIES

Polypeptides

Highly potent antibodies binding to death receptor 5

Methods for manipulating phagocytosis mediated by CD47

Therapeutic targeting of non-cellular structures

TREATMENT OF CANCER WITH COMBINATIONS OF IMMUNOREGULATORY AGENTS

CD137 antibodies and PD-1 antagonists and uses thereof

Reducing systemic regulatory T cell levels or activity for treatment of amyotrophic lateral sclerosis

Anti-human 4-1BB antibodies and uses thereof

Anti-OX40 antibodies and methods of use

TARGETED IMMUNOTOLERANCE WITH A PD-1 AGONIST

Methods of Treating Metabolic Disease

Bispecific antigen binding molecules capable of specific binding to CD40 and to fap

Reducing systemic regulatory T cell levels or activity for treatment of amyotrophic lateral sclerosis

Compositions and methods for using the CD2-based signaling pathways to block HIV infection

APOPTOTIC CELL-MEDIATED INDUCTION OF ANTIGEN SPECIFIC REGULATORY T-CELLS FOR THE THERAPY OF AUTOIMMUNE DISEASES IN ANIMALS AND HUMANS

FGF21 mimetic antibodies and uses thereof

ANTIBODIES AND METHODS OF USE THEREOF

Anti-vista antibodies and fragments, uses thereof, and methods of identifying same

Antibodies to ICOS

Anti-CD27 antibodies and uses thereof

ANTIBODY-MODIFIED CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELL AND USES THEREOF

Antibodies directed to Tie-2 and methods of use

Anti-GITR antibodies and uses thereof

AGONISTIC ANTIBODIES THAT BIND CD40

LYMPHOCYTE ANTIGEN CD5-LIKE (CD5L) MONOMER, HOMODIMER, AND INTERLEUKIN 12B (P40) HETERODIMER AGONISTS AND METHODS OF USE THEREOF

Antibodies to CD40 with enhanced agonist activity

Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment

ANTI-CD40 ANTIBODIES IN COMBINATION AND METHODS OF USE

COMPOSITIONS AND METHODS FOR TREATING ALLERGIC DISORDERS

Monoclonal antibodies activating CD40 and uses thereof

ASSAYS FOR DETECTING T CELL IMMUNE SUBSETS AND METHODS OF USE THEREOF

ANTIBODY SUBSTITUTING FOR FUNCTION OF BLOOD COAGULATION FACTOR VIII

MEDICINAL COMPOSITION USABLE FOR PREVENTING AND/OR TREATING BLOOD COAGULATION FACTOR IX ABNORMALITY, COMPRISING MULTISPECIFIC ANTIGEN BINDING MOLECULE REPLACING FUNCTION OF BLOOD COAGULATION FACTOR VIII

Anti-CD137 antibodies and methods of use thereof

Antibodies that bind CD3 epsilon

Antibodies that specifically bind PD-1 and methods of use

FIXaxFX bispecific antibody with common light chain

Glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies and methods of use thereof

Anti-Siglec-9 antibodies and methods of use thereof

Targeted immunotolerance

Anti-MET agonist antibody for use in the treatment of colorectal cancer

C-MET agonistic antibody and use thereof

Anti-GITR antibodies and methods of use thereof

Trispecific and/or trivalent binding proteins

Method for making pluripotent stem cells

Factor X binders enhancing FX activation

METHODS FOR PURIFYING ANTIBODIES

Polynucleotides encoding death domain-containing receptor-5 (DR5) binding molecules

Markers of acute myeloid leukemia stem cells

Antibodies to programmed cell death protein 1

ANTI-TIGIT ANTIBODIES AND METHODS OF USE

Methods of treating nonalcoholic steatohepatitis comprising administering an anti-human beta klotho antibody or binding fragment thereof

Anti-EGFR/anti-4-1BB bispecific antibody

ANTI-TNFRSF25 ANTIBODIES

ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF

Multivalent binding molecules

Antagonists targeting the TGF-β pathway

VECTOR CO-EXPRESSING VACCINE AND COSTIMULATORY MOLECULES

CD137 antibodies for T-cell activation

Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof

Antibodies against OX-40 and uses thereof

Anti-TrkB antibodies

Use of bispecific antigen-binding molecules that bind MUC16 and CD3 in combination with 4-1BB co-stimulation

Low energy immune priming for treating cancer and metastasis

HUMAN TNFRSF25 ANTIBODY

Natriuretic peptide receptor 1 antibodies and methods of use

Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors

Anti-OX40 binding proteins

Anti-CD137 antibodies

Agonistic antibodies that bind human CD40 and uses thereof

Antigen-binding molecule comprising altered antibody variable region binding CD3 and CD137

Anti-CD277 antibodies

Immunostimulatory agonistic antibodies for use in treating cancer

Method for treating cancer using anti-CD137 antibody

Methods of inducing or enhancing an immune response comprising administering agonistic anti-CD40 antibodies

Methods for expansion or depletion of T-regulatory cells

MOLECULES THAT BIND TO CD137 AND PSMA

Single domain antibodies that bind to CD137

NOVEL TNFR AGONISTS AND USES THEREOF

Antibodies Directed Against ICOS and Uses Thereof

Compositions and methods for immunotherapy

Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists, and immunotoxins

Anti-GITR antibodies and methods of use thereof

Inert format

ANTIBODIES OR ANTIGEN-BINDING PORTIONS BINDING CD40 AND USES THEREOF

Antibodies targeting CD137 and methods of use thereof

Bispecific antibodies binding ALK-1 and BMPR-2

ANTIBODIES BINDING TO HUMAN AND CYNOMOLGUS CD3 EPSILON

Anti-coagulation factor XI antibodies

ANTI-PD-1 ANTIBODIES AND THEIR USES

Antibodies and methods of use thereof

Methods of administering anti-OX40 antibodies

BISPECIFIC ANTIBODY

Anti-TREM2 antibodies and methods of use thereof

Compositions and methods for the treatment of immune related diseases

HINGE MODIFIED ANTIBODY FRAGMENTS AND METHODS OF MAKING

Anti-coagulation factor XI antibodies

CD137 antibodies and tumor antigen-targeting antibodies and uses thereof

Agonist antibodies that bind human CD137 and uses thereof